Physician profile
James E Fanning
NPI 1861443897
$1,490.85
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,003 · 2020: $133 · 2021: $354.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $606.09 | 2019 | |
| Jazz Pharmaceuticals INC. | $163.10 | 2021 | |
| Rigel Pharmaceuticals, INC. | $160.62 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $137.94 | 2019 | |
| Janssen Biotech, INC. | $113.99 | 2019-2020 | |
| Kite Pharma, INC. | $72.64 | 2019 | |
| Tesaro, INC. | $41.27 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $36.70 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $30.04 | 2019-2020 | |
| Boston Scientific Corporation | $24.88 | 2021 | |
| Blue Earth Diagnostics | $23.83 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $19.20 | 2020 | |
| Lilly USA, LLC | $18.16 | 2021 | |
| Merck Sharp & Dohme LLC | $17.83 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.64 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $11.92 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Fanning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.